Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 12/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10593744 | 0.84 | CA2 (0.52) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL29805242 | 0.83 | PTGES2 (0.45) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL14812406 | 0.81 | CCR4 (0.40) | PTGES2CCR4 | |
| SCHEMBL20485996 | 0.81 | CA2 (0.45) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL2049215 | 0.81 | CCR4 (0.40) | PTGES2CCR4 | |
| SCHEMBL10356224 | 0.79 | TTR (0.41) | PTGES2CDK2CCR4 | |
| SCHEMBL6239644 | 0.79 | CCR4 (0.46) | PTGES2CYP2C9CCR4 | |
| SCHEMBL29578190 | 0.78 | PTGES2 (0.64) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL742940 | 0.78 | PTGES2 (0.64) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL789494 | 0.78 | PTGES2 (0.64) | PTGES2CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891130-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| EP-4201924-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2020117634-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
| CN-105175284-A | Amide compounds, preparation method and medical use thereof | UNIV CHINA PHARMA | 2015-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | PTGES2 2323/4885CA2 4217/4885CA1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.